Abstract
Introduction Corona Virus-induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.
Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.
Aim of Study To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients
Patients and Population 265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab), group (B) received remdesivir, and group (C) received favipravir.
Methods The study design is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH) and prescribed by chest diseases lectures of the faculty of medicine-Mansoura University. The duration of the study is about 6 months after ethical approval.
Results and discussion Casirivimab and imdevimab achieve less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O2 therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower World Health Organization (WHO) scale and better multi-organ functions as presented by lower Sequential Organ Function Assessment (SOFA) score than Remdesivir and Favipravir.
Conclusion From all of these results, it is concluded that Group A (Casirivimab & imdevimab) has more favorable clinical outcomes than B (remdesivir) & C (favipravir) intervention groups.
Clinical Trial Registration: NCT05502081, 16/08/2022, Clinicaltrials.gov, retrospectively registered
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05502081
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Tanta university gave ethical approval for this work IRB of Mansoura University gave ethical approval for this work Ethics committee of Egyptian Ministry of health gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
this version is more grammatically and spelling accurate than previous versions
Data Availability
All data produced in the present work are contained in the manuscript
https://drive.google.com/drive/folders/1X1dDQwW9vBvusutwMbeebUjN8jJqYxsh?usp=sharing
